Biological treatment options for severe asthma in Poland
DOI:
https://doi.org/10.12775/JEHS.2024.70.51135Keywords
severe asthma, asthma, asthma treatments, biologics, monoclonal antibodiesAbstract
Intruduction and purpose: Patients with severe asthma account for approximately 3% to 10% of all asthma patients. They have higher hospital utilization rates and treatment costs than patients with non-severe asthma. Previously, treatment options for these patients were limited due to unacceptable side effects. However, the advent of biologic therapies has provided promising targeted therapy for these patients.
State of knowledge: Biologic therapies target inflammatory modulators that play a key role in the pathogenesis of asthma, particularly in patients with high T2 cells. These therapies have shown promising results in reducing asthma symptoms, improving lung function, decreasing the use of oral corticosteroids, and enhancing patients' quality of life.
Conclusions: This article reviews the mechanism of action, efficacy, and indications of currently approved biologic drugs available in Poland, as well as potential therapeutic targets for the future.
References
Global Initiative for Asthma. Gina Main Report. Global Initiative for Asthma; Fontana, WI, USA: 2022. [Google Scholar]
"Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma." Advances in Therapy, 2024. DOI: 10.1007/s12325-024-02803-2
Hekking P.-P.W., Wener R.R., Amelink M., Zwinderman A.H., Bouvy M.L., Bel E.H. The Prevalence of Severe Refractory Asthma. J. Allergy Clin. Immunol. 2015;135:896–902. DOI: 10.1016/j.jaci.2014.08.042.[PubMed] [CrossRef]
Marone G., Spadaro G., Braile M., Poto R., Criscuolo G., Pahima H., Loffredo S., Levi-Schaffer F., Varricchi G. Tezepelumab: A Novel Biological Therapy for the Treatment of Severe Uncontrolled Asthma. Expert Opin. Investig. Drugs. 2019;28:931–940. DOI: 10.1080/13543784.2019.1672657.
Côté A., Godbout K., Boulet L.-P. The Management of Severe Asthma in 2020.Biochem. Pharmacol. 2020;179:114112. DOI: 10.1016/j.bcp.2020.114112.
Rajizadeh, M.A., Najafipour, H., & Bejeshk, M.A. (2024). "An Updated Comprehensive Review of Plants and Herbal Compounds with Antiasthmatic Effect." Evidence-Based Complementary and Alternative Medicine. DOI: https://www.hindawi.com/journals/ecam/2024/5373117/.
Lui JK, Lutchen KR. The role of heterogeneity in asthma: a structure‐to‐function perspective. Clinical and Translational Medicine. 2017;6(1). DOI:10.1186/s40169-017-0159-0
Nadif R, Siroux V, Oryszczyn MP, et al. Heterogeneity of asthma according to blood inflammatory patterns. Thorax. 2009;64(5):374-380. DOI:10.1136/thx.2008.103069
Papi A, Brightling CE, Pedersen S, Reddel HK. Asthma. Lancet. 2018;391(10122):783-800. DOI:10.1016/s0140-6736(17)33311-1
Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? Thorax. 1999; 54:268–72. DOI: 10.1136/thx.54.3.268.
Russell RJ, Brightling C. Pathogenesis of asthma: implications for precision medicine. Clin Sci (Lond). 2017; 131:1723–35. DOI: 10.1042/CS20160253.
Diver S, Russell RJ, Brightling CE. New and emerging drug treatments for severe asthma. Clin Exp Allergy. 2018; 48:241–52. DOI: 10.1111/cea.13086.
McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019; 199:433–45. DOI: 10.1164/rccm.201810-1944CI.
Pavord ID, Afzalnia S, Menzies-Gow A, Heaney LG. The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clin Exp Allergy. 2017; 47:148–60. DOI: 10.1111/cea.12881.
Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res. 2006; 7:135. DOI: 10.1186/1465-9921-7-135.
Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002; 57:875–9. DOI: 10.1136/thorax.57.10.875.
Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med. 2015; 7:301ra129. DOI: 10.1126/scitranslmed.aab3142.
Godar M, Blanchetot C, de Haard H, Lambrecht BN, Brusselle G. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. MAbs. 2018; 10:34–45. DOI: 10.1080/19420862.2017.1392425.
Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017; 390:659–68. DOI: 10.1016/S0140-6736(17)31281-3.
Jahnz-Różyk K, Kucharczyk A. Modern therapies in allergology and pneumonology. Issue 1. Warsaw 2021. PZWL. Polish.
REPORT Drug program B.44 Treatment of patients with severe asthma. Version 2.0. September 2023. Cracow 2023. Polish.
Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2014;2:525–536, e1. DOI: 10.1016/j.jaip.2014.03.010.
Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003;112:252–262. DOI: 10.1067/mai.2003.1595.
Manka LA, Wechsler ME. Selecting the right biologic for your patients with severe asthma. Ann Allergy Asthma Immunol 2018;121:406–413
McCracken JL, Tripple JW, Calhoun WJ. Biologic therapy in the management of asthma. Curr Opin Allergy Clin Immunol 2016;16: 375–382. DOI: 10.1097/ACI.0000000000000284.
Annex B.44. Treatment of patients with severe asthma. ICD-10: J45, J82. From 04-2024. Polish. Programy lekowe - Ministerstwo Zdrowia - Portal Gov.pl (www.gov.pl)
Walsh GM. An update on biologic-based therapy in asthma. Immunotherapy 2013;5:1255–1264. DOI: 10.2217/imt.13.118.
Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, et al. Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. BioMed Res Int 2018;2018:4839230. DOI: 10.1155/2018/4839230.
Pepper AN, Renz H, Casale TB, Garn H. Biologic therapy and novel molecular targets of severe asthma. J Allergy Clin Immunol Pract 2017;5:909–916. DOI: 10.1016/j.jaip.2017.04.038.
Marone G, Spadaro G, Braile M, Poto R, Criscuolo G, Pahima H, Loffredo S, Levi-Schaffer, Varricchi G. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. Epub 2019 Oct 10. DOI: 10.1080/13543784.2019.1672657
Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017;17:78. DOI: 10.1038/nrd.2017.201.
Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001;108:250–257. DOI: 10.1067/mai.2001.116576.
Lightwood D, Tservistas M, Zehentleitner M, Sarkar K, Turner A, Bracher M, et al. Efficacy of an inhaled IL-13 antibody fragment in a model of chronic asthma. Am J Respir Crit Care Med 2018;198: 610–619. DOI: 10.1164/rccm.201712-2382OC.
Holguin F. Biological treatments for eosinophilic asthma enter the airways. Am J Respir Crit Care Med 2018;198:551–552. DOI: 10.1164/rccm.201807-1205ED
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Maciej Superson, Klaudia Wilk-Trytko, Katarzyna Szmyt, Sylwia Samojedny, Katarzyna Szymańska, Kamil Walczak, Julia Krasnoborska, Julia Zarębska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 191
Number of citations: 0
